37.60

10.49% +3.57

Neurogene Inc (NGNE)

Overview News Price History Financials Discussions Forecast

Neurogene Inc stock is currently priced at $37.60, with a 24-hour trading volume of 138.02K. It has seen a +10.49% increased in the last 24 hours and a +9.05% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $33.56 pivot point. If it approaches the $36.44 resistance level, significant changes may occur.

Previous Close:

$34.03

Open:

$34.68

24h Volume:

138.02K

Market Cap:

$488.06M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+17.10%

1M Performance:

+9.05%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1D Range:

$34.33

$38.33

52W Range:

$15.19

$53.00

Neurogene Inc Stock (NGNE) Company Profile

Name

Neurogene Inc

Sector

Healthcare (1198)

Industry

Biotechnology (691)

Phone

(877) 237-5020

Address

535 W 24th Street, 5th Floor, New York

Employee

Twitter

Next Earnings Date

2024-06-14

Latest SEC Filings

NGNE's Discussions on Twitter

Neurogene Inc Stock (NGNE) Latest News

Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

MarketBeat

Neurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of “Buy” by Brokerages - Defense World

Defense World

HC Wainwright Brokers Decrease Earnings Estimates for Neurogene Inc. (NASDAQ:NGNE) - MarketBeat

MarketBeat

Q2 2024 EPS Estimates for Neurogene Inc. (NASDAQ:NGNE) Boosted by Analyst - Defense World

Defense World

Neurogene (NASDAQ:NGNE) Price Target Cut to $51.00 - Defense World

Defense World

Neurogene (NASDAQ:NGNE) Given New $51.00 Price Target at HC Wainwright - MarketBeat

MarketBeat

Neurogene Inc Stock (NGNE) Financials Data

There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.